This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
A number of generic drug companies participated in an “at-risk” launch of generic versions of a blockbuster branded drug used to treat epilepsy. The generic companies launched “at-risk” by selling product after receiving FDA marketing approval, but while claims of patent infringement were still pending. Upon generic entry, annual sales of the branded drug declined from multiple billions of dollars to the low hundreds of millions of dollars. The branded drug company asserted a multi-billion dollar claim of lost profits against the generic drug companies.
Intensity was called upon to quantify the percentage of sales of the generic drug that resulted from off-label promotion of the branded drug and to evaluate commercial success of the branded drug. The Court found that Intensity’s findings were relevant to the determination of both patent damages and patent validity.
Intensity performed statistical modeling of sales, competition, physician prescribing behavior, and network effects to quantify the amount of sales attributable to off-label promotion. Intensity calculated the portion of branded drug sales that were driven by off-label promotional activities separate and apart from other factors that influenced sales. Intensity also calculated sales attributable to lasting economic effects of the off-label promotion that persisted after the off-label promotion had ceased. In a pretrial order, the Court stated that “the jury may consider [sales attributable to off-label promotion] as one of the many complex factors it will weigh in calculating appropriate damages in this case.”
Intensity also performed an economic analysis of commercial success, which is a secondary consideration relating to non-obviousness and patent validity. Intensity answered the question of whether sales of the branded drug were driven by patented technology or other economic factors. Intensity performed an analysis of the patented technology, other technologies contributing to sales, sales of acceptable non-infringing alternatives, and other factors to arrive at a conclusion regarding commercial success of the technology claimed in the patent-in-suit.
Secretariat Expert Testimony Helps Secure Win in Complex Real Estate Investment Fraud Litigation
Managing Director Ryan Marsh, PhD provided an expert report and testimony in a high-stakes case involving real estate investment fraud. A Houston jury found in favor of the plaintiff, based in part on Dr. Marsh’s testimony.
Secretariat Expert Valuation Helps Secure Historic $5.89 Billion Citgo Sale Order
In a complex federal court case in Delaware with far-reaching geopolitical significance, Managing Director Gary Kleinrichert’s expert financial valuation helped secure approval of a landmark $5.89 billion Citgo sale opinion that could help resolve billions of dollars in unpaid judgments against Venezuela and certain of its instrumentalities.
Secretariat Named Arbitration Expert Firm of the Year at 2025 Lexology Index Awards
Secretariat is delighted to announce that we were named as the Arbitration Expert Firm of the Year at the prestigious 2025 Lexology Index Awards Ceremony, held at Merchant Taylors’ Hall in London. We are honored to be recognized by clients and peers as the foremost experts leading and shaping the global arbitration community.